Abstract library

559 results for "long-acting somatostatin analogues".
#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors
Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Joël Guigay
#549 Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors
Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected with functioning well-differentiated neuroendocrine tumors (NET). There are no studies specifically focusing on NET associated to Multiple Endocrine Neoplasia type 1 (MEN-1).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Antongiulio Faggiano
#2946 Analysis of Factors Related to Gallstones in Patients with Neuroendocrine Tumors Treated with Long-Acting Somatostatin Analogues
Introduction: Somatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Zhirong Qi
Authors: Qi Z, Zhang Y, Li Y, Shi Y, ...
#392 A 67-Year Old Woman with a Carcinoid Tumor of the Coccyx with Liver Metastases
Introduction: Neuroendocrine tumors (NETs) are tumors of the interface between the endocrine and nervous system. They are characterized by the presence of secretory granules, as well as the ability to produce biogenic amines and polypeptide hormones. The clinical behavior of NETs is extremely variable; they may be functioning or non-functioning, ranging from very slow-growing tumors, which are the majority, to highly aggressive and very malignant tumors. Many case reports of rare sites of primary NETs outside the gastrointestinal tract have been described, as tumors with neuroendocrine characteristics can occur in virtually any organ or tissue. Nevertheless, this is the first case of a metastatic coccygeal carcinoid tumor ever described.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Theodors Angelopoulos
#735 Efficacy of Somatostatin Analogues (SSAs) in Patients with Neuroendocrine Tumors (NETs) According to the 2010 WHO Classification of NET: A Multicentric Study
Introduction: SSAs have recently been demonstrated to have antiproliferative effects in ileal NETs. No data are available on SSA efficacy according to 2010 WHO NET categories.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Antongiulio Faggiano
#190 Complete Remission in a Patient with Metastatic Type 1 Gastric Carcinoid (GCA1) Treated with a Long-acting Somatostatin Analogue
Introduction: Surgery is the treatment of choice for invasive and metastatic GCA1. Somatostatin analogues have been successfully used in GCA1 patients without signs of malignancy.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr merav Fraenkel
#2105 Long-Acting Somatostatin Analogue (LA-SSA) Treatment Durations in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden
Introduction: The main pharmacological treatment for metastatic GEP-NET G1/G2 is LA-SSA.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Daniel Granfeldt
#2106 Long-Acting Somatostatin Analogue (LA-SSA) Treatment Patterns in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden
Introduction: The main pharmacological treatment for metastatic GEP-NET G1/G2 is LA-SSA.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Daniel Granfeldt
#901 Impact of Long-Acting Octreotide in Patients with Early-Stage MEN1-Related Duodeno-Pancreatic Neuroendocrine Tumors
Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected by functioning well-differentiated neuroendocrine tumors (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Valeria Ramundo
#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis
Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Marion Feuilly